To test whether H3K27me3 could contribute to risk stratification in mutated patients despite cytogenetic risk group, we compared OS between patients with H3K27me3low and H3K27me3high in FLT3-ITD, FLT3-D835, NPM1, DNMT3A, TP53, RAS, IDH1, IDH2, TET2 wildtype and mutated AML (Fig. 4). This evidence concerns the gene DNMT3A and acute myeloid leukemia.